Paclitaxel-carboplation in advanced ovarian cancer

This study included 85 female patients with advanced ovarian epithelial cancer. Fifty patients were subjected to primary optimal debulking surgery, followed by adjuvant combination chemotherapy either cisplatin-cyclophosphamide or paclitaxel-carboplatin with comparable treatment outcome. The other 35 cases were not amenable to optimal surgery. They received primary chemotherapy, either cisplatin-cyclophosphamide or paclitaxel-carboplatin. The overall median duration of response and survival in this subgroup was 12 and 28 months, respectively, which was significantly lower than in those subjected to primary optimal debulking surgery [22 and 35 months, respectively]. However, in the subgroup of patients who received primary chemotherapy [paclitaxel-carboplatin], the median duration of response and survival was significantly higher than those received cisplatin-cyclophosphamide and comparable with those patients subjected to primary debulking surgery and adjuvant chemotherapy. Also, the treatment related toxicity was significantly higher among the patients receiving cisplatin-cyclophosphamide

Activity of single agent oxaliplatin in recurrent ovarian cancer, previously treated with cisplatin or carboplatin

This study included 28 females with recurrent ovarian cancer previously treated with combination chemotherapy including cisplatin or carboplatin. The platinum free interval was >6 - <12 months in 11 patients and >12 months in 17 patients. Oxaliplatin was prescribed in a dose of 130 mg/m2 administered over 2 hours every 21 days with an average of 5 cycles/patient. An overall response was achieved in ten patients with a median time to tumor progression and overall survival of 11 and 17 months, respectively. A favorable response was observed in the platinum sensitive group [platinum free interval of >12 months] as well as those cases with non-bulky recurrent disease. Oxaliplatin administration was associated with an accepted level of drug related toxicity